Other evidence indicated that the IGF1R inhibitor PPP affected autophagy and improved the therapeutic efficacy of PD-1 blockade in cancer-bearing mice, underscoring the capacity of the IGF1R antagonist to enhance chemoimmunotherapy efficacy in preclinical models [87]. This evidence concerns the gene IGF1R and cancer.